US5662929A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Therapeutic liposomal formulation
Assignee: University of Montreal
•
Filing: 1994-12-23
•
Granted: 1997-09-02
•
Expires: 2014-12-23
Abstract
Abstract The invention relates to a liposomal formulation containing a therapeutic agent. The formulation of the invention when administered to animals, allows a substantial increase in antibacterial activity of the agent, through an enhanced penetration of the agent inside the bacterial cell. More specifically, the invention relates to a liposomal formulation containing at least one therapeutic agent such as an antibiotic and to a method of treatment of bacterial infections through the administration of such a formulation.
Inventors
- 👤 Jacqueline Lagace
- 👤 Christian Beaulac
- 👤 Sebastien Clement-Major
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-10-23 19:52
CPC Classifications
A; A61; A61K; A61K31/00; A61K31/70; A61K31/7028; A61K31/7034; A61K31/7036; A61K9/00; A61K9/0012; A61K9/007; A61K9/0073; A61K9/10; A61K9/127; A61P; A61P31/00; A61P31/04; Y; Y02; Y02A; Y02A50/00; Y02A50/30
Claims Analysis
Total Claims: 12
Claim 1
Independent Claim
78 words
A low rigidity liposomal formulation, free of cholesterol and phospholipids with high phase transition temperature (T C ) comprising a neutral and anionic phospholipids at a molar ratio of 5:1 to 20:1 wherein the mean value of T C is below 37° C. or below the body temperature of the animal to be treated and at least one antimicrobial agent, wherein the liposomal formulation enhances the penetration of the antimicrobial agent inside a bacterial cell by direct interaction.
Claim 2
Dependent Claim
78 words
A low rigidity liposomal formulation, free of cholesterol and phospholipids with high phase transition temperature (T C ) comprising a neutral and anionic phospholipids at a molar ratio of 5:1 to 20:1 wherein the mean value of T C is below 37° C. or below the body temperature of the animal to be treated and at least one antimicrobial agent, wherein the liposomal formulation enhances the penetration of the antimicrobial agent inside a bacterial cell by direct interaction.
Claim 3
Dependent Claim
25 words
The liposomal formulation of claim 1, wherein the neutral phospholipid and the anionic phospholipid are present at a ratio of from about 7.5 to 17.5:1.
Claim 4
Dependent Claim
24 words
The liposomal formulation of claim 1, wherein the neutral phospholipid and the anionic phospholipid are present at a ratio of about 10:1 to 15:1.
Claim 5
Dependent Claim
20 words
The liposomal formulation of claim 3, wherein the neutral phospholipid is dipalmitoylphosphatidylcholine (DPPC) and the anionic phospholipid is dimirystoylphosphatidylglycerol (DMPG).
Claim 6
Dependent Claim
20 words
The liposomal formulation of claim 1, wherein the antimicrobial agent is tobramycin at concentration from 1 ug/ml to 50 mg/ml.
Claim 7
Dependent Claim
20 words
The liposomal formulation of claim 3, wherein the antimicrobial agent is tobramycin at concentration from 1 ug/ml to 50 mg/ml.
Claim 8
Dependent Claim
20 words
The liposomal formulation of claim 4, wherein the antimicrobial agent is tobramycin at concentration from 1 ug/ml to 50 mg/ml.
Claim 9
Dependent Claim
36 words
The liposomal formulation of claim 1, wherein the formulation enhances the passage by direct interaction with bacteria of the at least one antimicrobial agent through at least one of the bacterial outer membrane and exopolysaccharide layer.
Claim 10
Dependent Claim
26 words
Method of treating a bacterial infection in mammals comprising an administration of an antimicrobial suitable dose of the liposomal formulation of claim 1 to said mammals.
Claim 11
Dependent Claim
31 words
Method of treatment of a mucoid variant of a bacterial infection in mammals comprising an administration of a suitably acceptable form of the liposomal formulation of claim 7 to said mammals.
Claim 12
Dependent Claim
35 words
Method of treatment according to claim 10, wherein the bacteria is Pseudomonas aeruginosa, Burkholderia cepacia, Xanthomonas maltophilia, Escherichia coli, or Staphylococcus aureus and the mammal is a human with cystic fibrosis or with chronic infection.
References Cited (Backward Citations)
US4235871A
Cited
US4981692A
Cited
US4753788A
Cited
US4952405A
Cited
US5006343A
Cited
WO1993023015A1
Cited
WO1994012155A1
Cited
WO1994012156A1
Cited
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 2000-09-01 | 2001-03-03 | 2001-09-02 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 2004-09-01 | 2005-03-03 | 2005-09-02 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 2008-09-01 | 2009-03-03 | 2009-09-02 | $7700.00 | Window Closed / Lapsed |